// App-Quantinova.ai

6030 : Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC).

Researchers

Presenter

  • Neus Baste

Principal Investigators

  • Irene Brana

  • David Viros

  • Jorge Pamias

  • Juan Lorente

  • Jordi Giralt

  • Coro Bescos

  • Margarita Alberola

  • Ana Vivancos

  • Paolo Nuciforo

  • Rodrigo Dienstmann

  • Josep M. del Campo

  • Josep Tabernero

  • Enriqueta Felip

  • Jordi Rodon

Medical Centers

  • Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain

  • Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain

  • Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain

  • Oral and Maxillofacial Surgery Department, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Pathology Laboratory, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain

  • Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Barcelona, Spain

  • Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Barcelona, Spain

  • Vall d'Hebron University Hospital, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved